Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO)

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1673-1678

  Ciardiello, F ^a   Arnold, D ^b   Casali, P G ^c   Cervantes, A ^d   Douillard, J Y ^e   Eggermont, A ^f   Eniu, A ^g   Mcgregor, K ^h   Peters, S ⁱ   Piccart, M ^j   Popescu, R ^k   van Cutsem, E ^l   Zielinski, C ^m   Stahel, R ⁿ  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b TUMOR BIOLOGY CENTER   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Instituto Universitario IVI INCLIVA   (Spain)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^h ESMO HEAD OFFICE   (Switzerland)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j JULES BORDET INSTITUTE   (Belgium)

^k Hirslanden Hospital   (Switzerland)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; B RAF KINASE; BCR ABL PROTEIN; CISPLATIN; CRIZOTINIB; IMATINIB; TRASTUZUMAB; TUMOR MARKER; VEMURAFENIB; ANTHRACYCLINE; BIOLOGICAL MARKER; IVACAFTOR;

BCR ABL FUSION GENE; BRAF GENE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARDIOMYOPATHY; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENETIC SCREENING; GENOMICS; HEALTH CARE KNOWLEDGE ENGINEERING; HEALTH INSURANCE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL EDUCATION; MEDICAL INFORMATICS; MELANOMA; MOLECULAR EVOLUTION; MOLECULARLY TARGETED THERAPY; ONCOGENE NEU; ONCOLOGY; OTOTOXICITY; PATIENT EDUCATION; PERSONALIZED MEDICINE; PHENOTYPIC VARIATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SOMATIC MUTATION; CANCER GENETICS; CYSTIC FIBROSIS; DRUG COST; DRUG RESISTANCE; EUROPE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH ECONOMICS; MEDICAL SOCIETY; MOLECULAR GENETICS; NON SMALL CELL LUNG CANCER; PATIENT SAFETY; TREATMENT RESPONSE; GENETICS; NEOPLASMS; PROCEDURES; PROTEOMICS;

CYSTIC FIBROSIS; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906858239     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu217     Document Type: Editorial

References (45)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Hughes TP, Kaeda J, Branford S et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
3. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
4. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
5. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464: 993-998.
6. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153: 17-37.
7. Stratton MR. Journeys into the genome of cancer cells. EMBO Mol Med 2013: 5: 169-172.
8. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013; 339: 1563-1566.
9. Ross CJ, Katzov-Eckert H, Dubé MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
10. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1: 158-163.
11. Yang Y, Muzny DM, Reid JG et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med 2013; 369: 1502-1511.
12. Kulkarny S, Ma P. Personalised Medicine: The Way Forward. Palo Alto, CA: McKinsey and Company 2012.
13. Burrell RA, McGranahan N, Bartek J et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345.
14. Gerlinger M, Horswell S, Larkin J et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-233.
15. Burrell RA, Swanton C. The evolution of the unstable cancer genome. Curr Opin Genet Dev 2014; 24: 61-67.
16. Dienstmann R, Rodon J, Barretina J et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 2013; 31: 1874-1884.
17. Yap TA, Gerlinger M, Futreal PA et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 127: 127ps10.
18. Swanton C. Cancer evolution: the final frontier of precision medicine? Ann Oncol 2014; 25: 549-551.
19. NCT01888601. http://clinicaltrials.gov/show/NCT01888601 (May 2014, date last accessed).
20. Cancer Research UK news. http://www.cancerresearchuk.org/about-us/cancernews/press-release/new-research-to-revolutionise-understanding-of-lung-cancer. (May 2014, date last accessed).
21. Table of Pharmacogenomic Biomarkers in Drug Labels. United States Food and Drug Administration; www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (17 October 2013, date last accessed).
22. Use of '-omics' technologies in the development of personalised medicine. European Commission. Brussels. 2013; http://ec.europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf (17 October 2013, date last accessed).
23. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31: 1815-1824.
24. van Krieken JH, Siebers AG, Normanno N. Quality assurance for molecular pathology group. European consensus conference for external quality assessment in molecular pathology. Ann Oncol 2013; 24: 1958-1963.
25. Aurora. Breast International Group; www.bigagainstbreastcancer.org (25 November 2013, date last accessed).
26. Lungscape. European Thoracic Oncology Platform; www.etop.ch (25 November 2013, date last accessed).
27. SPECTAcolor. European Organisation for Research and Treatment of Cancer; www. spectacolor.eortc.org (25 November 2013, date last accessed).
28. Mello MM, Francer JK, Wilenzick M et al. Preparing for responsible sharing of clinical trial data. N Engl J Med 2013; 369: 1651-1658.
29. Beck T, Gollapudi S, Brunak S et al. Knowledge engineering for health: a new discipline required to bridge the "ICT gap" between research and healthcare. Hum Mutat 2012; 33: 797-802.
30. Lolkema MP, Gadellaa-van Hooijdonk CG, Bredenoord AL et al. Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol 2013; 31: 1842-1848.
31. Buettner R, Heydt C. Biomarker analysis from a pathologist's view: founding the rationale for personalised treatment of lung cancer. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 1502-1508.
32. Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health 2013; 16 (6 Suppl): S32-S38.
33. Leopold C, Voglera S, Habla C et al. Personalised medicine as a challenge for public pricing and reimbursement authorities-a survey among 27 European countries on the example of trastuzumab. Health Policy 2013; 113: 313-322.
34. Nelson R. GICS 2009: huge saving from KRAS testing in metastatic colorectal cancer. Medscape 16 January 2009.
35. Djalalov S, Beca J, Hoch JS et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive nonsmall- cell-lung cancer. J Clin Oncol 2014; 32: 1012-1019.
36. Buzyn A. Developing patient-centric cancer services for the 21st century. Ann Oncol 2012; 23(Suppl 9):ix66.
37. Van Dyck W, Gassull D, Vértes G et al. Unlocking the value of personalised healthcare in Europe-breast cancer stratification. Health Policy Technol 2012; 1: 63-68.
38. European Personalised Medicine Association (EPEMED); http://www.epemed.org/(May 2014, date last accessed).
39. Personalised Medicine Coalition; http://www.personalizedmedicinecoalition.org/(May 2014, date last accessed).
40. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013; 31: 1858-1865.
41. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31: 1806-1814.
42. Popescu RA, Schäfer R, Califano R et al. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2014; 25(1): 9-15.
43. Mardis ER. The translation of cancer genomics: time for a revolution in clinical cancer care. Genomic Med 2014; 6: 22.
44. Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii56-vii64.
45. Piccart M. Personalised cancer management: closer, but not here yet. Ann Oncol 2013; 24: 1951-1955.